Cannabinoids dosing for osteoarthritis-authors' reply.
作者信息
Pramhas Sibylle, Sator Sabine, Kress Hans G
机构信息
Department of Special Anaesthesia and Pain Therapy, Medical University of Vienna, Austria.
出版信息
Lancet Reg Health Eur. 2024 Feb 2;38:100851. doi: 10.1016/j.lanepe.2024.100851. eCollection 2024 Mar.
Abstract
摘要
相似文献
1
Cannabinoids dosing for osteoarthritis-authors' reply.
Lancet Reg Health Eur. 2024 Feb 2;38:100851. doi: 10.1016/j.lanepe.2024.100851. eCollection 2024 Mar.
2
Editorial: cannabis use disorders at the emergency department, a sign of a growing cannabinoid emergency-authors' reply.
Aliment Pharmacol Ther. 2023 Jan;57(1):149. doi: 10.1111/apt.17316.
3
Authors' reply to Braillon and Bewley, Spiller and colleagues, and Wu.
BMJ. 2019 Sep 23;366:l5622. doi: 10.1136/bmj.l5622.
4
Statin use and osteoarthritis. The authors’ reply.
J Gen Intern Med. 2013 Sep;28(9):1135. doi: 10.1007/s11606-013-2478-1.
5
Osteoarthritis in 2020 and beyond - Authors' reply.
Lancet. 2021 Mar 20;397(10279):1060. doi: 10.1016/S0140-6736(21)00205-1.
6
Authors' reply to Liedgens and Henske: "cost-utility analysis of duloxetine in osteoarthritis: a US private payer perspective".
Appl Health Econ Health Policy. 2013 Oct;11(5):555-7. doi: 10.1007/s40258-013-0049-6.
7
OARSI recommended performance-based tests to assess physical function in osteoarthritis of the hip or knee: authors' reply.
Osteoarthritis Cartilage. 2013 Oct;21(10):1625-6. doi: 10.1016/j.joca.2013.07.011. Epub 2013 Jul 21.
8
Dolutegravir dosing with rifampicin - Authors' reply.
Lancet HIV. 2023 Oct;10(10):e636. doi: 10.1016/S2352-3018(23)00230-8. Epub 2023 Sep 14.
9
Optimal dosing of antidepressant drugs - Authors' reply.
Lancet Psychiatry. 2019 Oct;6(10):806-807. doi: 10.1016/S2215-0366(19)30339-6.
10
Re: Effectiveness of platelet-rich plasma in the management of hip osteoarthritis: a systematic review and meta-analysis: authors' reply.
Clin Rheumatol. 2020 Dec;39(12):3903-3904. doi: 10.1007/s10067-020-05426-4. Epub 2020 Oct 3.
本文引用的文献
1
Cannabinoids dosing for osteoarthritis.
Lancet Reg Health Eur. 2024 Jan 30;38:100850. doi: 10.1016/j.lanepe.2024.100850. eCollection 2024 Mar.
2
Oral cannabidiol (CBD) as add-on to paracetamol for painful chronic osteoarthritis of the knee: a randomized, double-blind, placebo-controlled clinical trial.
Lancet Reg Health Eur. 2023 Nov 10;35:100777. doi: 10.1016/j.lanepe.2023.100777. eCollection 2023 Dec.
3
Cannabidiol (CBD) in Rheumatic Diseases (Musculoskeletal Pain).
Curr Rheumatol Rep. 2022 Jul;24(7):238-246. doi: 10.1007/s11926-022-01077-3. Epub 2022 May 3.
4
Psychiatric symptoms caused by cannabis constituents: a systematic review and meta-analysis.
Lancet Psychiatry. 2020 Apr;7(4):344-353. doi: 10.1016/S2215-0366(20)30074-2. Epub 2020 Mar 17.
5
European Pain Federation (EFIC) position paper on appropriate use of cannabis-based medicines and medical cannabis for chronic pain management.
Eur J Pain. 2018 Oct;22(9):1547-1564. doi: 10.1002/ejp.1297. Epub 2018 Sep 4.
6
The pharmacokinetics and the pharmacodynamics of cannabinoids.
Br J Clin Pharmacol. 2018 Nov;84(11):2477-2482. doi: 10.1111/bcp.13710. Epub 2018 Aug 7.
7
Effect of Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome.
N Engl J Med. 2018 May 17;378(20):1888-1897. doi: 10.1056/NEJMoa1714631.
8
Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome.
Neurology. 2018 Apr 3;90(14):e1204-e1211. doi: 10.1212/WNL.0000000000005254. Epub 2018 Mar 14.
9
Acute psychotropic effects of oral cannabis extract with a defined content of Delta9-tetrahydrocannabinol (THC) in healthy volunteers.
Pharmacopsychiatry. 2010 Jan;43(1):24-32. doi: 10.1055/s-0029-1237397. Epub 2009 Dec 10.
Zotero 插件